RetInSight and veonet launch comprehensive collaboration to improve AMD care
RetInSight, a pioneer in AI-based image analysis of retinal diseases, and veonet, a leading network of ophthalmology care centers in several countries, including Germany, Switzerland, and the UK, have entered into a commercial agreement. This agreement allows veonet to integrate RetInSight’s software solutions, the Fluid Monitor and the GA Monitor, into their clinical routine. Both AI-based software solutions are certified under MDR 2017/745.
The software provides eye doctors by mouse click with an easy-to-understand PDF report for their patients with age-related macular degeneration (AMD) by mouse click. This report sustainably supports diagnostics and monitoring of this serious disease, facilitating efficient patient management.
Corinna zur Bonsen-Thomas, CEO of RetInSight, says:
“We are pleased that after the successful completion of our joint pilot project, we were able to establish a comprehensive collaboration with veonet. The precise localization and quantification of biomarkers for wet AMD and geographic atrophy can significantly improve diagnostics, increase productivity, and strengthen patient confidence in therapy. With our software we can help the many patients with AMD to preserve their vision.”
Prof. Dr. Ulrich Kellner, member of veonet’s medical board, comments:
“In light of increasing patient numbers and the limited availability of medical and non-medical staff in healthcare, new approaches are necessary to provide patients with timely, efficient, highly qualified, and individualized treatment. We believe that AI-based image analysis will be an essential component of future patient care. It standardizes evaluations and allows for the identification of high-risk patients and the development of personalized treatment plans based on long-term progression. RetInSight’s AI-based software meets our requirements, and together, we have the opportunity to tailor future developments based on our experiences.”
About the RetInSight Fluid Monitor
The RetInSight Fluid Monitor is an AI-based software for the precise and automatic evaluation of OCT images in clinical routine. It allows doctors to instantly recognize and quantify disease-specific fluids in various retinal layers. These fluid accumulations are key indicators of the activity of neovascular age-related macular degeneration (nAMD, wet AMD). The Fluid Monitor provides a clear and visualized PDF report, offering a practical and high-quality basis for assessing disease progression and tailoring treatment for optimal outcomes.
About the RetInSight GA Monitor
The RetInSight GA Monitor is an AI-based software for the interpretation of OCT images as part of the management of geographic atrophy (GA), the dry form of AMD.
This disease leads to severe, irreversible vision loss. The GA Monitor visualizes, localizes and quantifies the degeneration of the photoreceptors (PR) and the loss of the retinal pigment epithelium (RPE) in the retina long before this is recognizable in clinical routine. Within minutes, it creates a clear, one-page PDF report that is available to the ophthalmologist at the click of a mouse.
The software thus enables, for the first time, a comprehensive and early recording of the activity and stage of GA, which was previously not possible for the ophthalmologist using routine methods. In addition, the report’s easy-to-understand images support patient communication in this serious chronic disease.
About veonet
veonet was founded by renowned ophthalmologists who recognized the benefits of sharing expertise, networking, and best practices to continuously improve the ophthalmic care of their patients. veonet not only offers top-notch service and high-quality care but also provides a positive environment for specialists and staff to develop both personally and professionally.
veonet is a growing network of more than 275 clinics across five countries, collaborating with all health insurance providers and supporting national healthcare systems. Each year, veonet ophthalmologists conduct approximately 2.7 million eye examinations and perform over 500,000 surgeries.
About RetInSight
RetInSight GmbH, based in Vienna, was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable people to maintain their full vision in order to preserve their quality of life and lifelong autonomy. We are therefore developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to monitor and detect progressive retinal diseases such as GA, neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most important age-related diseases that lead to visual impairments in today’s world. Our mission is to revolutionize ophthalmology through reliable, affordable, and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases for anyone, any time and at any location by supporting networked care in ophthalmology with the help of AI technology and digital data.
Contact
RetInSight GmbH
Klaudia Schuh, Head of Marketing & Communications
Tel: +43 677 610 749 47
E-Mail: klaudia.schuh@retinsight.com
www.retinsight.com